author-photo

Axel Hoos

GlaxoSmithKline
Bristol-Myers Squibb
Memorial Sloan Kettering Cancer Center

160

Papers

15014

Citations

Citation Trend

Filter By

Papers (160) Sort By

Journal Conference Others

Industrializing engineered autologous T cells as medicines for solid tumours.

2021 Nature Reviews Drug Discovery
Show All
- Source
- Cite
- Save
Citations (2)
390 A global, molecular disease characterization initiative (MDCI) in oncology clinical trials

2021 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 1849: ICOS co-stimulation in combination immune checkpoint blockade and/or dose-optimized focal irradiation results in enhanced tumor control

2021 Immunology
Show All
- Source
- Cite
- Save
Citations (0)
Inducible T-cell co-stimulatory (ICOS) receptor agonist, feladilimab (fela), alone and in combination (combo) with pembrolizumab (P): Results from INDUCE-1 urothelial carcinoma (UC) expansion cohorts (ECs).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract CT033: Inducible T cell costimulatory (ICOS) receptor agonist, feladilimab (FE), alone and in combination (combo) with pembrolizumab (PE): Results from INDUCE-1 relapsed/refractory (R/R) melanoma expansion cohorts (EC)

2021 Clinical Trials
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 2816: Immuno-PET monitoring of CD8+T cell infiltration post anti-ICOS agonist antibody treatment alone and in combination with PD-1 blocking antibody using a89Zr anti-CD8+mouse minibody in EMT 6 syngeneic tumor mouse

2021 Tumor Biology
Show All
- Source
- Cite
- Save
Citations (0)
Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-Mediated Anti-Tumor Responses In Vivo

2021 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (0)
Immunodynamics of explanted human tumors for immuno‐oncology

2021 Embo Molecular Medicine
Show All
- Source
- Cite
- Save
Citations (2)
Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs).

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (20)
MM-219: Pivotal DREAMM-2 Study: Single-Agent Belantamab Mafodotin (Belamaf; GSK2857916) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Proteasome Inhibitors and Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 Monoclonal Antibodies (mAbs), Including Subgroups with Renal Impairment (RI) and High-Risk (HR) Cytogenetics

2020 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (1)